GPR39-C3 - GPR39 Agonist. CAS# 1621175-65-2 size:2 mg solid is a novel potent and

is a novel potent and selective inhibitor of ubiquitin-specific protease 7 (USP7) with an IC50 ~4

is a potent ErbB inhibitor for the treatment of cancer

PKCδ and PKCζ with IC50 of 7 nM

and STAT-3

GPR39-C3 - GPR39 Agonist. CAS# 1621175-65-2 size:2 mg solid is a novel potent andGPR39 C3, CAS No. 1621175 65 2, is the first potent, selective and orally bioavailable GPR39 agonist with an EC50 ~0. 8 nM for human GPR39 and ~0. 4 nM for rodent GPR39. It has no inhibitory effects (at 10 M) on a panel of kinases and exhibits no relevant binding affinity for the related ghrelin and neurotensin 1 receptors and other enzymes, transporters, and GPCRs. GPR39 C3 has excellent functional activity in physiologically relevant rodent cells